Crossmark

JAK inhibitors, cardiovascular and thromboembolic events: what we know and what we would like to know

Published Online: 2022-12-13

Published Print: 2023-03

Authors

Evangelatos, Gerasimos https://orcid.org/0000-0003-3822-3093
Fragoulis, George E. https://orcid.org/0000-0003-4932-7023
License Information

Text and Data Mining valid from 2022-12-13

Version of Record valid from 2022-12-13
More Information

Article History

Received: 11 November 2022

Revised: 29 November 2022

Accepted: 2 December 2022

First Online: 13 December 2022

Declarations

:

: GE has no conflicts of interest to declare. GEF has received honoraria/speaker fees from AbbVie, Aenorasis, UCB, Novartis, Lilly, Pfizer, and Janssen.

Document is current